Multifarious factors attenuate the efficiency of the PD-1 inhibitor in treating GBM patients, including extensive tumor heterogeneity, low tumor mutation burden (TMB), T-cell dysfunction and exhaustion, and DNA mismatch repair (dMMR) system status (165–167). This evidence concerns the gene PDCD1 and glioblastoma.